Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sichuan Haisco Pharmaceutical is an R&D-driven pharma company with a focus on small molecules and peptides for indications including pain management, metabolic diseases, cardiovascular conditions, anti-infectives, digestive system disorders, mental health conditions, liver disease and metabolic system disorders. The company has several innovative drugs at various stages from preclinical to registration/approval in China. Notable recent approvals include ciprofol for sedation and anrikefon for postoperative pain. The company also develops generics and has robust GMP-compliant manufacturing capabilities.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sichuan Haisco Pharmaceutical.